Prospective studies should clarify the predictive role of PD-L1 in BRAF-mutant NSCLC, directly compare ICIs and anti-BRAF/MEK therapy in Class I mutations and identify optimal strategies for treating non-Class I mutations such as intensified or combination ICI strategies in those with STK11/KEAP1 co-alterations. This evidence concerns the gene STK11 and non-small cell lung carcinoma.